Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist.
about
The SYK side of TLR4: signalling mechanisms in response to LPS and minimally oxidized LDLA structure-function approach to optimizing TLR4 ligands for human vaccinesA Novel Agonist of the TRIF Pathway Induces a Cellular State Refractory to Replication of Zika, Chikungunya, and Dengue Viruses.Identification of Adjuvantic Activity of Amphotericin B in a Novel, Multiplexed, Poly-TLR/NLR High-Throughput Screen.Activation of innate immune responses by Haemophilus influenzae lipooligosaccharideToll-like receptor 4 (TLR4) modulation by synthetic and natural compounds: an update.Structure-activity relationships in human Toll-like receptor 8-active 2,3-diamino-furo[2,3-c]pyridines.Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella entericaSingle-cell and population NF-κB dynamic responses depend on lipopolysaccharide preparation.Inefficient TLR4/MD-2 heterotetramerization by monophosphoryl lipid ACharacterization of TRIF selectivity in the AGP class of lipid A mimetics: role of secondary lipid chains.Kdo2 -lipid A: structural diversity and impact on immunopharmacology.Type I interferon signaling contributes to the bias that Toll-like receptor 4 exhibits for signaling mediated by the adaptor protein TRIF.Adjuvants in the Driver's Seat: How Magnitude, Type, Fine Specificity and Longevity of Immune Responses Are Driven by Distinct Classes of Immune PotentiatorsDifferential outcome of TRIF-mediated signaling in TLR4 and TLR3 induced DC maturationA unique host defense pathway: TRIF mediates both antiviral and antibacterial immune responses.Pharmacological characterization of the opioid inactive isomers (+)-naltrexone and (+)-naloxone as antagonists of toll-like receptor 4TRIF mobilizes unique primary defense against Gram-negative bacteria in intestinal interface.HIV-1 Tat Protein Activates both the MyD88 and TRIF Pathways To Induce Tumor Necrosis Factor Alpha and Interleukin-10 in Human Monocytes.Src-kinase inhibitors sensitize human cells of myeloid origin to Toll-like-receptor-induced interleukin 12 synthesis.Adjuvant activity of naturally occurring monophosphoryl lipopolysaccharide preparations from mucosa-associated bacteriaMyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvantIntranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection.The immunobiology of toll-like receptor 4 agonists: from endotoxin tolerance to immunoadjuvants.Adjuvants containing natural and synthetic Toll-like receptor 4 ligands.Directing the immune system with chemical compounds.Small-Molecule Carbohydrate-Based Immunostimulants.Old and new adjuvants.Synthesis of anti-inflammatory α-and β-linked acetamidopyranosides as inhibitors of toll-like receptor 4 (TLR4).TLR4 agonists as vaccine adjuvants: a chemist's perspective.TLR4-mediated pro-inflammatory dendritic cell differentiation in humans requires the combined action of MyD88 and TRIF.Funiculosin variants and phosphorylated derivatives promote innate immune responses via the Toll-like receptor 4/myeloid differentiation factor-2 complex.Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis.The Toll like receptor 4 ligand cold-inducible RNA-binding protein as vaccination platform against cancer.Improved vaccines through targeted manipulation of the body's immunological risk-assessment?
P2860
Q26991782-119C836D-A4DD-4B0E-B546-71D845E62D5AQ28818147-A279F19A-2E92-44E5-9EAF-61A285D3BD3FQ30145658-FCDB9F8B-F272-4F7A-A4F2-0256CE3C3C21Q30388683-BF41EC7C-FF82-43EF-94DC-D55208B372C2Q33601866-A1AC266B-1DD9-4E69-802A-36ED29F293F2Q33693637-46D14E64-891E-43F4-9C5E-8F0266E123EEQ34394100-C4E11055-57A2-4210-9112-543FE76C3D44Q34446653-6B6CC950-0623-42E4-81D7-08AC25443FD9Q34542388-0C71C080-742E-44D8-AA41-1CE032C5B56BQ34701875-06610C81-F6C3-4CD5-B036-E71302F43E16Q35088222-2267C7B8-BA76-4D3E-8796-D6D10E1D9649Q35468441-F10CE1CB-23CE-4EE6-AAFC-7D1DA2ADB82BQ35695840-65591492-E094-455D-BE88-84B29FD778A4Q35826747-90AD1A7D-DF80-4DA7-AD73-41B7B75C4D75Q36300342-8D0F3355-342C-4EB2-964B-7BFB9C6E6F22Q36511199-DE977020-CF45-4EC8-A001-1985DC8CCE38Q36599638-90E06F36-8908-4D1B-9968-E5C852AC2FEEQ36920092-3EBDAC6D-EB08-4388-B508-F02AF33FCF78Q37002574-FB15446A-C051-4D3E-9D28-E1498F2B85A9Q37098840-4EDA9553-6B11-4EDA-AAD3-3E134BCFDBEFQ37123782-7F85A588-DA3F-451C-A8E1-94924A7D8763Q37243896-253ED510-3DFA-4FF3-A8B2-9B7D81ADAF28Q37510582-5BD4F9BE-2536-422D-B796-3C4F5A99BB87Q37572673-F4F4FF5A-A7F2-4948-B7D9-6475BA3325B9Q38124063-195F07A1-EAED-4509-89B9-4236E6D18407Q38201155-188198F4-9180-4F0C-A016-E5790BC65733Q38844616-1D9CCADD-A74C-40E3-9D71-B8ED1F2681BDQ39451745-06565405-01E5-4125-BEBF-0621C6359914Q41882467-B4788950-5892-40A8-9C27-3E42919C2A0FQ43603547-0A0DF965-1891-4A9F-9C68-08F44C2F9E2DQ45988450-6BB29383-C0AD-4902-A404-57B1B24F932EQ46329132-58C32B16-5002-4C54-A5BA-6CE1B5F23F85Q51830691-19FEBDCE-A15C-4983-A42C-F5B9F13F6BE8Q52597551-FCE61B6D-CB3D-4D9A-B947-04D543D55E5BQ52887434-0B80FD8E-4475-4EC4-9441-68EE4FD7C249
P2860
Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist.
@en
type
label
Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist.
@en
prefLabel
Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist.
@en
P2093
P2860
P1433
P1476
Selective TRIF-dependent signaling by a synthetic toll-like receptor 4 agonist
@en
P2093
David A Johnson
Laurie A Minns
Melinda M Hutton
Thomas C Mitchell
William S Bowen
P2860
P356
10.1126/SCISIGNAL.2001963
P50
P577
2012-02-14T00:00:00Z